This observation can be supported by recent studies that have demonstrated a tumorigenic effect of GPR84 in both esophageal cancer via attenuation of the antitumor CD8+ T-cell response [45] as well as in prostate cancer via its activation by the metabolite caprylic acid [46]. Here, CD8A is linked to prostate carcinoma.